Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Little Matthew, Wolstenholme Jane, Landeiro Filipa, Marian Ioana R, Williams Roxanne, Francisco Lopez J, Mercader Claudia, Raslan Mutie, Berridge Christopher, Whitburn Jessica, Campbell Teresa, Tuck Steve, Barber Vicki S, Scaife Jessica, Hewitt Aimi, Taylor Amy, Ooms Alexander, Ghosh Sukanya, Reynard John M, Hamdy Freddie C, Liew Matthew P C, Leslie Tom, Catto James W F, Rosario Derek J, Omer Altan, Good Daniel W, Gray Rob, Kommu Sashi, Chung Daniel, Wells Hannah, Narahari Krishna, Macpherson Ruth E, Verrill Clare, Eddy Ben, Yamamoto Hide, Bryant Richard J, Lamb Alastair D, TRANSLATE Trial Study Group
Аннотация
METHODS: Between December 2021 and September 2023, the TRANSLATE randomised clinical trial allocated 1126 men to receive either a TRUS (n = 564) or an LATP (n = 562) biopsy at ten sites in the UK. All men were biopsy naïve and underwent prebiopsy MRI. Participants were followed up for 4 mo after a biopsy. The economic analysis is a within-trial analysis at 4 mo after biopsy, conducted from a National Health Service perspective. We assessed resource use, health care costs, and quality-adjusted life years (QALYs) across 4 mo of follow-up from an intention-to-treat perspective. We addressed missing data using multiple imputation. Incremental cost-effectiveness ratios were calculated, with uncertainty characterised using nonparametric bootstrapping. The TRANSLATE trial is registered at ISRCTN (ISRCTN98159689) and is complete.
KEY FINDINGS AND LIMITATIONS: The total mean costs over the 4 mo of follow-up were £1062 in the LATP arm and £917 in the TRUS arm (adjusted mean difference £149; 95% confidence interval [CI] £61-236, p = 0.001). The total mean QALYs at 4 mo were 0.282 in the LATP arm and 0.284 in the TRUS arm (adjusted mean difference -0.004; 95% CI -0.009 to 0.001, p = 0.098).
CONCLUSIONS AND CLINICAL IMPLICATIONS: An LATP biopsy has a higher mean cost, and no significant difference in mean QALYs, compared with a TRUS biopsy at 4 mo after the procedure. A time of 4 mo is too soon to reflect any impact from the 5.7% diagnostic uplift for LATP versus TRUS biopsy on the detection of intermediate-/high-grade prostate cancer seen in the TRANSLATE trial. A further analysis beyond this period is needed to fully interpret the cost-effectiveness results.